Summary & Overview

O.R. Procedures for Obesity without CC/MCC: Inpatient Reimbursement Overview

DRG 621 encompasses inpatient admissions for operating room procedures for obesity without Complication or Comorbidity or Major Complication or Comorbidity; it covers primary bariatric surgeries performed in patients without additional significant diagnoses. Accurate assignment of this Diagnosis-Related Group is important for inpatient reimbursement because it determines the base Medicare payment and resource-classification for these surgical admissions.

O.R. Procedures for Obesity without CC/MCCDRG O.R. Procedures for Obesity without CC/MCCDRG 621Diagnosis-Related GroupInpatient ReimbursementMedicareBariatric SurgerySurgeryHospital Finance

DRG 621 Overview

DRG 621 covers inpatient admissions for patients undergoing operating room procedures specifically for obesity when there is no Complication or Comorbidity and no Major Complication or Comorbidity present. This group captures primary surgical interventions such as bariatric procedures performed without additional significant diagnoses that would increase resource use. It matters for Medicare payment because bundling into this Diagnosis-Related Group determines base reimbursement and influences hospital revenue for straightforward obesity operations. Payer classification under DRG 621 affects length of stay expectations and relative payment weights for these admissions.

National Payment Rates

Across commercial payers the DRG rate benchmarks range from about $1.1K (BCBS p25) up to $57K (Anthem max), with typical median rates clustering around $23K–$25K depending on payer. The widest spread is observed between the Anthem maximum ($57K) and BCBS lower quartile values (around $1.1K), reflecting substantial variation across payers; see the table and chart below for payer-specific distributions. Reported payer medians are approximately $23K–$25K for Anthem, Aetna, Cigna and BCBS.

Mean Rates by Payer — National — DRG 621

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Across payers in Alaska for DRG 621, negotiated mean rates range from $22K (BCBS and Anthem) up to $34K (Cigna), with medians clustering near $23K for BCBS and Anthem and $24K for Cigna. Cigna represents the most notable deviation, paying substantially more than the other local payers and above several national comparators. Reference the table and chart below for payer-level distributions and percentile detail.

Key Insights for Alaska

Highest payer: Cigna (mean $34K) is the highest-paying payer in Alaska; lowest payers: BCBS and Anthem (both mean $22K).
Cigna’s mean ($34K) sits noticeably above the Alaska median range and is meaningfully higher than other local payers, exceeding national mean benchmarks for some payers; BCBS/Anthem cluster below national means for similar payers.

Clinical Trials

Perioperative risk-reduction and enhanced recovery studies: randomized or prospective cohort studies that test preoperative optimization bundles (e.g., weight-loss programs, nutritional assessment, glycemic control, and pulmonary/cardiac risk stratification) versus standard preoperative care for adults undergoing bariatric or other obesity-related O.R. procedures without major complications. These trials enroll elective surgical patients with class II–III obesity or obesity-related comorbidities to evaluate intraoperative metrics (operative time, blood loss), short-term morbidity, and length of stay. Results inform hospitals and payers on which preoperative interventions most effectively reduce resource utilization and unplanned escalations of care in this DRG.
Comparative effectiveness trials of surgical techniques and approaches: pragmatic head-to-head studies comparing minimally invasive techniques, different anastomotic methods, or variations in procedure type (for example, comparing procedure A versus procedure B within obesity surgery) in patients who are otherwise uncomplicated (no CC/MCC). These trials focus on differences in operative efficiency, complication rates within 30 days, readmission, and functional outcomes such as weight loss and resolution of metabolic comorbidities, enrolling typical inpatient candidates for O.R. procedures for obesity. Payers and clinical leaders use this evidence to guide procedure selection, credentialing, and bundled payment design because small differences in complication or readmission rates markedly affect reimbursement and DRG resource use.
Post-discharge outcomes and long-term utilization cohort studies: longitudinal observational studies following patients discharged after O.R. procedures for obesity without CC/MCC to assess rehospitalization, outpatient utilization, quality-of-life, and cost trajectories over 6–24 months. These studies often stratify by discharge disposition, outpatient follow-up intensity, and adherence to lifestyle interventions to identify predictors of downstream utilization and late complications such as nutritional deficiencies or need for revision. Findings help payers and health systems design post-discharge care pathways, transitional care programs, and risk-sharing arrangements that optimize long-term outcomes and control total episode costs associated with this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$14K	$69K	$10K	6.3K

Perioperative risk-reduction and enhanced recovery studies: randomized or prospective cohort studies that test preoperative optimization bundles (e.g., weight-loss programs, nutritional assessment, glycemic control, and pulmonary/cardiac risk stratification) versus standard preoperative care for adults undergoing bariatric or other obesity-related O.R. procedures without major complications. These trials enroll elective surgical patients with class II–III obesity or obesity-related comorbidities to evaluate intraoperative metrics (operative time, blood loss), short-term morbidity, and length of stay. Results inform hospitals and payers on which preoperative interventions most effectively reduce resource utilization and unplanned escalations of care in this DRG.
Comparative effectiveness trials of surgical techniques and approaches: pragmatic head-to-head studies comparing minimally invasive techniques, different anastomotic methods, or variations in procedure type (for example, comparing procedure A versus procedure B within obesity surgery) in patients who are otherwise uncomplicated (no CC/MCC). These trials focus on differences in operative efficiency, complication rates within 30 days, readmission, and functional outcomes such as weight loss and resolution of metabolic comorbidities, enrolling typical inpatient candidates for O.R. procedures for obesity. Payers and clinical leaders use this evidence to guide procedure selection, credentialing, and bundled payment design because small differences in complication or readmission rates markedly affect reimbursement and DRG resource use.
Post-discharge outcomes and long-term utilization cohort studies: longitudinal observational studies following patients discharged after O.R. procedures for obesity without CC/MCC to assess rehospitalization, outpatient utilization, quality-of-life, and cost trajectories over 6–24 months. These studies often stratify by discharge disposition, outpatient follow-up intensity, and adherence to lifestyle interventions to identify predictors of downstream utilization and late complications such as nutritional deficiencies or need for revision. Findings help payers and health systems design post-discharge care pathways, transitional care programs, and risk-sharing arrangements that optimize long-term outcomes and control total episode costs associated with this DRG.

OpenPayer

Summary & Overview

O.R. Procedures for Obesity without CC/MCC: Inpatient Reimbursement Overview

DRG 621 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes